Gossamer Bio Files 8-K for Other Events

Ticker: GOSS · Form: 8-K · Filed: 2025-02-19T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, regulatory-filing

TL;DR

Gossamer Bio filed an 8-K for 'Other Events' - standard reporting.

AI Summary

Gossamer Bio, Inc. filed an 8-K on February 19, 2025, to report other events. The filing does not contain specific details about the nature of these events, but it confirms the company's reporting obligations under the Securities Exchange Act of 1934. The company is incorporated in Delaware and headquartered in San Diego, California.

Why It Matters

This filing indicates Gossamer Bio is fulfilling its regulatory reporting requirements, which is standard practice for publicly traded companies.

Risk Assessment

Risk Level: low — This is a routine filing to report 'Other Events' without disclosing specific material information, indicating no immediate significant risk.

Key Numbers

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by Gossamer Bio, Inc. in this 8-K filing?

The filing does not specify the nature of the 'Other Events' beyond categorizing them as such.

When was this 8-K filing submitted to the SEC?

The filing was submitted on February 19, 2025.

What is Gossamer Bio, Inc.'s principal executive office address?

The principal executive offices are located at 3013 Science Park Road, San Diego, California, 92121.

Under which section of the Securities Exchange Act of 1934 is this report filed?

This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

What is Gossamer Bio, Inc.'s SEC File Number?

Gossamer Bio, Inc.'s SEC File Number is 001-38796.

From the Filing

0001728117-25-000004.txt : 20250219 0001728117-25-000004.hdr.sgml : 20250219 20250219160112 ACCESSION NUMBER: 0001728117-25-000004 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250219 ITEM INFORMATION: Other Events FILED AS OF DATE: 20250219 DATE AS OF CHANGE: 20250219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Gossamer Bio, Inc. CENTRAL INDEX KEY: 0001728117 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 475461709 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38796 FILM NUMBER: 25639771 BUSINESS ADDRESS: STREET 1: 3115 MERRYFIELD ROW STREET 2: SUITE 120 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 922-0718 MAIL ADDRESS: STREET 1: 3115 MERRYFIELD ROW STREET 2: SUITE 120 CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 goss-20250219.htm 8-K goss-20250219 0001728117 FALSE 0001728117 2025-02-19 2025-02-19 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter)   Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)       3013 Science Park Road San Diego , California , 92121 (Address of Principal Executive Offices) (Zip Code) ( 858 ) 684-1300 (Registrant’s Telephone Number, Including Area Code) N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.0001 par value per share   GOSS   Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐ Item 8.01 Other Events. On February 19, 2025, Gossamer Bio, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) and the minimum bid price matter is now closed. The letter was pursuant to a previous letter received on September 11, 2024 from the Listing Qualifications Department of Nasdaq, indicating, as previously reported, that the Company was not then in compliance with the minimum bid price requirement because its common stock had failed to maintain a minimum bid price of $1.00 or more for 30 consecutive business days.   2 SIGNATURES Pursuant to the requir

View on Read The Filing